StockNews.com upgraded shares of Exact Sciences (NASDAQ:EXAS – Get Rating) from a sell rating to a hold rating in a report released on Friday morning.
Several other equities analysts also recently weighed in on EXAS. Craig Hallum reduced their target price on Exact Sciences from $100.00 to $81.00 in a research report on Wednesday. Citigroup cut their price objective on Exact Sciences from $80.00 to $65.00 in a report on Wednesday. The Goldman Sachs Group cut their price objective on Exact Sciences from $100.00 to $85.00 and set a buy rating on the stock in a report on Tuesday, April 19th. SVB Leerink cut their price objective on Exact Sciences from $140.00 to $130.00 and set an outperform rating on the stock in a report on Wednesday, February 23rd. Finally, Raymond James cut their price objective on Exact Sciences from $90.00 to $80.00 in a report on Wednesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of Buy and a consensus price target of $113.00.
EXAS opened at $55.05 on Friday. The company has a quick ratio of 2.56, a current ratio of 2.53 and a debt-to-equity ratio of 0.67. The firm has a market cap of $9.69 billion, a P/E ratio of -12.74 and a beta of 1.14. Exact Sciences has a 52 week low of $54.79 and a 52 week high of $133.99. The business’s fifty day simple moving average is $67.89 and its 200 day simple moving average is $77.81.
Exact Sciences (NASDAQ:EXAS – Get Rating) last released its earnings results on Tuesday, April 26th. The medical research company reported ($1.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.12) by $0.08. Exact Sciences had a negative return on equity of 21.82% and a negative net margin of 40.26%. During the same quarter in the prior year, the firm earned ($0.18) EPS. As a group, equities analysts expect that Exact Sciences will post -4.26 EPS for the current fiscal year.
In other Exact Sciences news, CFO Jeffrey Thomas Elliott sold 1,839 shares of the firm’s stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $79.55, for a total transaction of $146,292.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Sarah Condella sold 938 shares of Exact Sciences stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $79.55, for a total value of $74,617.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,636 shares of company stock worth $4,443,252. Company insiders own 1.40% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of EXAS. Mine & Arao Wealth Creation & Management LLC. grew its position in shares of Exact Sciences by 1,562.5% in the 3rd quarter. Mine & Arao Wealth Creation & Management LLC. now owns 266 shares of the medical research company’s stock worth $25,000 after acquiring an additional 250 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Exact Sciences in the 4th quarter worth approximately $28,000. FSB Premier Wealth Management Inc. acquired a new position in shares of Exact Sciences in the 4th quarter worth approximately $36,000. Masso Torrence Wealth Management Inc. acquired a new position in shares of Exact Sciences in the 4th quarter worth approximately $37,000. Finally, CarsonAllaria Wealth Management Ltd. acquired a new position in Exact Sciences during the 4th quarter valued at approximately $37,000. Institutional investors own 94.84% of the company’s stock.
About Exact Sciences (Get Rating)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.
Receive News & Ratings for Exact Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Exact Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.